NCT06747416View on ClinicalTrials.gov

KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

September 2, 2026

Study Completion Date

December 31, 2026

Conditions

Hemophilia a and B

Interventions

DRUG

KN057

KN057 will be administered subcutaneously once a week.

All Listed Sponsors

lead

Suzhou Alphamab Co., Ltd.

INDUSTRY